VLCC, has signed a license agreement with the Central Marine Fisheries Research Institute (CMFRI), thepremier Kochi-based marine research establishment of the Indian Council of Agricultural Research (ICAR), Government of India, for exclusive rights to manufacture, market and use Cadalmin™ Antihypercholesterolemic (Cadalmin™ ACe) extract.

These marine algae based nutraceutical product hasbeen developed after years of intensive research by CMFRI and has been found to be effective incombating dyslipidemia 1 and obesity.

As per CMFRI’s research, Cadalmin™ Ace provides a unique blend of 100 per cent natural marine bioactive ingredients from selected seaweeds known for their extraordinary medicinal properties, with an eco-friendly ‘green’ technology.

VLCC will be working closely with the CMFRI to source relevant seaweed and manufacture the product as per CMFRI developed technology.